Patents by Inventor Andre CHOLLET

Andre CHOLLET has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES
    Publication number: 20230226021
    Abstract: The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one-O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions. The present invention is furthermore related to processes for their preparation.
    Type: Application
    Filed: August 22, 2022
    Publication date: July 20, 2023
    Inventors: Andre CHOLLET, Oliver POHL
  • PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS
    Publication number: 20230097933
    Abstract: The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-meth19243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or vasopressin V1a receptor, to processes for their preparation, pharmaceutical compositions containing them and their use.
    Type: Application
    Filed: January 28, 2022
    Publication date: March 30, 2023
    Inventor: Andre CHOLLET
  • Oral formulations of pyrrolidine derivatives
    Patent number: 11419851
    Abstract: The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions. The present invention is furthermore related to processes for their preparation.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: August 23, 2022
    Assignee: ObsEva S.A.
    Inventors: Andre Chollet, Oliver Pohl
  • Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists
    Patent number: 11312683
    Abstract: The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-meth19243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or vasopressin V1a receptor, to processes for their preparation, pharmaceutical compositions containing them and their use.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: April 26, 2022
    Assignee: ObsEva S.A.
    Inventor: Andre Chollet
  • PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS
    Publication number: 20210047266
    Abstract: The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-meth19243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or vasopressin V1a receptor, to processes for their preparation, pharmaceutical compositions containing them and their use.
    Type: Application
    Filed: March 26, 2020
    Publication date: February 18, 2021
    Inventor: Andre CHOLLET
  • ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES
    Publication number: 20200281892
    Abstract: The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one-O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions. The present invention is furthermore related to processes for their preparation.
    Type: Application
    Filed: September 12, 2019
    Publication date: September 10, 2020
    Inventors: Andre CHOLLET, Oliver POHL
  • Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and methods of using the same
    Patent number: 10752583
    Abstract: Crystalline (3Z,S3)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime is disclosed. A pharmaceutical composition containing the crystalline compound and methods for treating conditions related to the OT-R activity, such as preterm labor, and for increasing embryo implantation rate in a mammal undergoing embryo transfer, comprising administering the crystalline compound are also disclosed.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: August 25, 2020
    Assignee: ObsEva S.A.
    Inventor: André Chollet
  • Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists
    Patent number: 10604482
    Abstract: The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-meth19243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or vasopressin V1a receptor, to processes for their preparation, pharmaceutical compositions containing them and their use.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: March 31, 2020
    Assignee: ObsEva S.A.
    Inventor: Andre Chollet
  • Oral formulations of pyrrolidine derivatives
    Patent number: 10478420
    Abstract: The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one-O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions. The present invention is furthermore related to processes for their preparation.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: November 19, 2019
    Assignee: ObsEva S.A.
    Inventors: Andre Chollet, Oliver Pohl
  • ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES
    Publication number: 20180311211
    Abstract: The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one-O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions. The present invention is furthermore related to processes for their preparation.
    Type: Application
    Filed: April 13, 2018
    Publication date: November 1, 2018
    Inventors: Andre CHOLLET, Oliver POHL
  • Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
    Patent number: 10047048
    Abstract: The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-meth19243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or vasopressin V1a receptor, to processes for their preparation, pharmaceutical compositions containing them and their use.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: August 14, 2018
    Assignee: ObsEva S.A.
    Inventor: Andre Chollet
  • PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS
    Publication number: 20180215708
    Abstract: The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-meth19243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or vasopressin V1a receptor, to processes for their preparation, pharmaceutical compositions containing them and their use.
    Type: Application
    Filed: March 28, 2018
    Publication date: August 2, 2018
    Inventor: Andre CHOLLET
  • Oral formulations of pyrrolidine derivatives
    Patent number: 9962367
    Abstract: The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one-O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions. The present invention is furthermore related to processes for their preparation.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: May 8, 2018
    Assignee: Obseva S.A.
    Inventors: Andre Chollet, Oliver Pohl
  • CRYSTALLINE (3Z,5S)-5-(HYDROXYMETHYL)-1-[(2'-METHYL-1,1'-BIPHENYL-4-YL)CARBONYL]PYRROLIDIN-3-ONE O-METHYLOXIME, AND METHODS OF USING THE SAME
    Publication number: 20170320822
    Abstract: Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime is disclosed. A pharmaceutical composition containing the crystalline compound and methods for treating conditions related to the OT-R activity, such as preterm labor, and for increasing embryo implantation rate in a mammal undergoing embryo transfer, comprising administering the crystalline compound are also disclosed.
    Type: Application
    Filed: May 25, 2017
    Publication date: November 9, 2017
    Inventor: André CHOLLET
  • PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1A RECEPTORS ANTAGONISTS
    Publication number: 20170240508
    Abstract: The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methl9243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or vasopressin V1a receptor, to processes for their preparation, pharmaceutical compositions containing them and their use.
    Type: Application
    Filed: March 31, 2017
    Publication date: August 24, 2017
    Inventor: Andre CHOLLET
  • Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and methods of using the same
    Patent number: 9718772
    Abstract: Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime is disclosed. A pharmaceutical composition containing the crystalline compound and methods for treating conditions related to the OT-R activity, such as preterm labor, and tor increasing embryo implantation rate in a mammal undergoing embryo transfer, comprising administering the crystalline compound are also disclosed.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: August 1, 2017
    Assignee: ObsEva S.A.
    Inventor: André Chollet
  • Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
    Patent number: 9670155
    Abstract: The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methy19243-yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or vasopressin V1a receptor, to processes for their preparation, pharmaceutical compositions containing them and their use.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: June 6, 2017
    Assignee: ObsEva S.A.
    Inventor: Andre Chollet
  • ORAL FORMULATIONS OF PYRROLIDINE DERIVATIVES
    Publication number: 20170065556
    Abstract: The present invention relates to solid oral formulations comprising a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one-O-methyloxime, and/or an active metabolite thereof, and the use of said formulations in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea and embryo implantation failure due to uterine contractions. The present invention is furthermore related to processes for their preparation.
    Type: Application
    Filed: December 15, 2014
    Publication date: March 9, 2017
    Inventors: Andre Chollet, Olivier Pohl
  • PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1a RECEPTORS ANTAGONISTS
    Publication number: 20160221944
    Abstract: The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1?-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methl9243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin receptor and/or vasopressin V1a receptor, to processes for their preparation, pharmaceutical compositions containing them and their use.
    Type: Application
    Filed: July 25, 2014
    Publication date: August 4, 2016
    Inventor: Andre CHOLLET
  • CRYSTALLINE (3Z,5S)-5-(HYDROXYMETHYL)-1-[(2'-METHYL-1,1'-BIPHENYL-4-YL)CARBONYL]PYRROLIDIN-3-ONE O-METHYLOXIME, AND METHODS OF USING THE SAME
    Publication number: 20160002160
    Abstract: Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2?-methyl-1,1-biphenyl-4-yl) carbonyl]pyrrolidin-3-one O-methyloxime is disclosed. A pharmaceutical composition containing the crystalline compound and methods for treating conditions related to the OT-R activity, such as preterm labor, and tor increasing embryo implantation rate in a mammal undergoing embryo transfer, comprising administering the crystalline compound are also disclosed.
    Type: Application
    Filed: June 10, 2015
    Publication date: January 7, 2016
    Inventor: André CHOLLET